Disc Medicine, Inc. (IRON)
NASDAQ: IRON · IEX Real-Time Price · USD
45.40
-0.79 (-1.71%)
At close: Jul 19, 2024, 4:00 PM
45.39
-0.01 (-0.02%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Disc Medicine Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Disc Medicine stock have an average target of 63.5, with a low estimate of 40 and a high estimate of 85. The average target predicts an increase of 39.87% from the current stock price of 45.40.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Disc Medicine stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 4 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +54.19% | Jul 10, 2024 |
| BMO Capital | BMO Capital | Buy Reiterates $50 → $70 | Buy | Reiterates | $50 → $70 | +54.19% | Jun 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $70 | Strong Buy | Reiterates | $70 | +54.19% | Jun 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $85 | Buy | Reiterates | $85 | +87.22% | May 28, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $85 | Buy | Reiterates | $85 | +87.22% | May 15, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-5.06
from -3.42
EPS Next Year
-5.52
from -5.06
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 13.1M | 38.9M | 223.8M |
| Avg | n/a | n/a | 2.7M | 27.9M | 145.3M |
| Low | n/a | n/a | n/a | 3.5M | 88.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 1,328.3% | 701.6% |
| Avg | - | - | - | 926.2% | 420.5% |
| Low | - | - | - | 29.4% | 216.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -4.36 | -4.70 | -4.68 | -5.16 | -0.58 |
| Avg | -5.06 | -5.52 | -6.37 | -6.86 | -3.59 |
| Low | -7.16 | -6.15 | -8.23 | -9.33 | -7.90 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.